Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Gurgaon, India-based Ranbaxy Laboratories has delayed plans to spin off its research unit until the second half of the year, but noted during a Jan. 17 press conference that it had settled a key lawsuit over Flomax (tamsulosin) and expanded a development deal with GlaxoSmithKline that will secure earnings momentum
Advertisement

Related Content

Astellas/Boehringer Get Flomax Market Exclusivity Extension Through Pediatric Study
Astellas/Boehringer Get Flomax Market Exclusivity Extension Through Pediatric Study
Ranbaxy To Announce New Drug Development Tie-Up In May
Eisai Fights To Maintain Aricept Patent Rights While Resuming Development On Next Generation Therapy
Ranbaxy And Teva Expected To Team Up For At Risk Launch Of Generic Nexium - Analysts
Indian Drug Majors Settle Generic Lawsuits
Anti-Pain Drugs Licensed To Lilly Boost Glenmark Earnings
Ranbaxy Board Approves Spin-off Of Drug Discovery Company
Ranbaxy Board Approves Spin-off Of Drug Discovery Company
Ranbaxy/GSK Partnership Yields First Drug Candidate
Advertisement
UsernamePublicRestriction

Register

SC066639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel